• Tonix Pharmaceuticals Holding Corp TNXP.OQ reported a quarterly adjusted loss of $3.86​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1,928.00. The mean expectation of two analysts for the quarter was for a loss of $3.21 per share. Wall Street expected results to range from $-3.51 to $-2.92 per share.

• Revenue fell 9.5% to $2.00 million from a year ago; analysts expected $2.43 million.

• Tonix Pharmaceuticals Holding Corp's reported EPS for the quarter was a loss of $3.86​.

• The company reported a quarterly loss of $28.27 million.

• Tonix Pharmaceuticals Holding Corp shares had risen by 71.1% this quarter and gained 86.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 52.9% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Tonix Pharmaceuticals Holding Corp is $65.00, about 5.3% above its last closing price of $61.57

This summary was machine generated from LSEG data August 14 at 09:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)